WinstonWınston
Profusa, Inc. Common Stock logo

Profusa, Inc. Common Stock

PFSA
Medical - Equipment & Services · Healthcare
Price
$1.73
-0.13 (-6.99%)
Market Cap
$38,531
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+3.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 322K (2021) → 335K (2025)

Profusa is a small medical technology company that makes tiny sensors designed to be injected under the skin. These sensors continuously monitor chemicals in the body — like oxygen or glucose — without needing to draw blood. The main customers are expected to be patients managing chronic conditions, military personnel, and healthcare providers who need real-time data on a person's health.

The company earns money by selling its sensor devices and potentially through data or monitoring services, though it remains in an early, pre-revenue stage. Profusa has received funding from DARPA, the U.S. military's research arm, which reflects its focus on both consumer health and defense applications. The financial data above — including zero gross margin and revenue — confirms the company is not yet generating meaningful commercial sales. The biggest risk is that Profusa must successfully complete clinical trials and win regulatory approval before it can sell its products widely, which requires significant time and continued outside funding.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+100.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$3M/ year

Rising (+74% vs prior year)

R&D investment increasing — building for the future

Insider Activity

84.3%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$375,000 cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Profusa, Inc. Common Stock has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
N/A
Data not available
Operating Margin
N/A
Data not available
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
N/A
Data not available
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial